Rapport Therapeutics, a Boston, MA and San Diego, CA-based clinical-stage biotechnology company dedicated to the discovery and development of precision medicines for neurological disorders, raised $100M in Series A funding.
The round was led by Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC.
The company intends to use the funds to accelerate growth, expand operations and its business reach.
Led by CEO Abraham Ceesay, and founder and Chief Scientific Officer, David Bredt, M.D., Ph.D., Rapport Therapeutics provides a novel platform that utilizes discoveries made by its scientific founders to identify receptor-associated proteins that enable the identification of precision targeted small molecule drugs that have the potential to transform the treatment of neurological disorders. Its lead program is currently in Phase 1 studies for the treatment of drug-resistant seizure disorders.
Mr. Ceesay brings nearly twenty years of leadership experience in the biopharmaceutical industry, most recently as President of the neuroscience company Cerevel Therapeutics and prior to that as CEO of the neuroendocrine company Tiburio Therapeutics.
FinSMEs
07/03/2023